Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Bullish +75

ABN AMRO Bank N.V. Acquires 220,969 Shares of Edwards Lifesciences ...

AI-generated analysis

📈 ABN AMRO Bank N.V. increased its EW holdings by 124.5% in Q1, adding 220,969 shares to reach a total value of $32.26 million.

🏦 State Street Corp grew its position by 1.5%, now holding 25.99 million shares valued at $2.22 billion.

📊 Wellington Management Group LLP raised its stake by 4.8% to own 21.79 million shares worth $1.86 billion.

🇳🇴 Norges Bank initiated a new stake in EW valued at $803.69 million during the fourth quarter.

📈 Morgan Stanley lifted its position by 12.4%, acquiring an additional 804,942 shares for $623.54 million.

🚀 Marshall Wace LLP significantly increased holdings by 66.1%, purchasing 2.36 million shares worth $505.16 million.

💰 Edwards Lifesciences reported Q1 EPS of $0.78, beating the consensus estimate of $0.73 by $0.05.

📈 Revenue reached $1.65 billion for the quarter, surpassing the $1.60 billion consensus and growing 16.7% year-over-year.

💹 The company achieved a net margin of 17.39% and a return on equity of 15.19% during the reporting period.

🎯 TD Cowen restated a 'buy' rating with an increased price target of $104.00, up from $97.00.

📉 VP Daniel J. Lippis sold 620 shares for $50,306.80 under a Rule 10b5-1 trading plan on May 18th.

💸 CFO Scott B. Ullem sold 13,000 shares for $1,040,520.00 on April 9th under a pre-arranged trading plan.

📉 Over the last ninety days, insiders sold a total of 81,038 shares valued at $6.68 million.

🏥 The company focuses on structural heart disease therapies, including the SAPIEN family of transcatheter heart valves.

🔮 Edwards Lifesciences provided FY 2026 EPS guidance ranging between $2.95 and $3.05.

Bullish Signals
  • ABN AMRO Bank N.V. increased its holdings in Edwards Lifesciences by 124.5% in the first quarter, adding 220,969 shares to a total holding of 398,425 shares valued at $32.26 million.
  • State Street Corp grew its position by 1.5% in the fourth quarter, now owning 25,991,524 shares worth $2.22 billion.
  • Wellington Management Group LLP raised its holdings by 4.8%, acquiring an additional 989,533 shares to reach a total value of $1.86 billion.
  • Norges Bank initiated a new stake in the company valued at $803.69 million during the fourth quarter.
  • Morgan Stanley lifted its position by 12.4%, purchasing an additional 804,942 shares worth $623.54 million.
  • Marshall Wace LLP grew its holdings by 66.1% in the fourth quarter, adding 2,359,128 shares valued at $505.16 million.
  • Edwards Lifesciences reported Q1 EPS of $0.78, beating the consensus estimate of $0.73 by $0.05.
  • Revenue for the quarter reached $1.65 billion, exceeding the consensus estimate of $1.60 billion and growing 16.7% year-over-year.
  • The company achieved a net margin of 17.39% and a return on equity of 15.19%, demonstrating strong profitability.
  • TD Cowen restated a 'buy' rating and raised its price target to $104.00 from $97.00 following the earnings beat.
  • Barclays restated an 'overweight' rating and increased its price target to $110.00 from $104.00.
  • Evercore reissued an 'outperform' rating with a price target of $93.00, indicating continued analyst confidence.
  • Mizuho set a price target of $95.00 and maintained an 'outperform' rating on the stock.
  • The consensus analyst price target is $95.96 with a 'Moderate Buy' rating based on 27 total analysts covering the stock.
Risk Factors
  • Company insiders sold a total of 81,038 shares valued at $6.68 million over the last ninety days.
  • VP Daniel J. Lippis sold 620 shares for $50,306.80 on May 18th, reducing his personal ownership by 1.51%.
  • CFO Scott B. Ullem sold 13,000 shares for $1,040,520.00 on April 9th, representing a 24.67% decrease in his position.
Full Analysis
ABN AMRO Bank N.V. significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 124.5% in the first quarter, purchasing an additional 220,969 shares. This brings ABN AMRO's total holding to 398,425 shares, valued at approximately $32.26 million as of their latest SEC filing. Other major institutional investors also expanded their positions during the fourth quarter, including State Street Corp, Wellington Management Group LLP, Norges Bank, Morgan Stanley, and Marshall Wace LLP, collectively signaling strong institutional confidence in the medical technology company. Edwards Lifesciences reported robust financial performance for the quarter ended April 23rd, beating analyst expectations on both earnings per share and revenue. The company posted $0.78 EPS compared to a consensus of $0.73, with revenue reaching $1.65 billion against an estimate of $1.60 billion. Year-over-year revenue growth was 16.7%, driven by strong demand for its structural heart disease products and critical care monitoring solutions. The company maintains healthy margins with a net margin of 17.39% and a return on equity of 15.19%. Analyst sentiment remains positive following the earnings beat, with several major firms raising price targets or restating buy ratings. TD Cowen raised its price target to $104.00, while Barclays increased its target to $110.00 and Evercore set a target of $93.00. The consensus analyst price target stands at $95.96 with a 'Moderate Buy' rating. Despite some insider selling by executives VP Daniel J. Lippis and CFO Scott B. Ullem under pre-arranged trading plans, the overall institutional accumulation suggests a bullish outlook for the stock.